Literature DB >> 28027448

Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.

Tanut Kunkanjanawan1,2,3, Richard Carter1,2, Kwan-Sung Ahn1,2, Jinjing Yang1,2, Rangsun Parnpai3, Anthony W S Chan1,2.   

Abstract

Huntington's disease (HD) is a neurodegenerative disease caused by an expansion of CAG trinucleotide repeat (polyglutamine [polyQ]) in the huntingtin ( HTT) gene, which leads to the formation of mutant HTT (mHTT) protein aggregates. In the nervous system, an accumulation of mHTT protein results in glutamate-mediated excitotoxicity, proteosome instability, and apoptosis. Although HD pathogenesis has been extensively studied, effective treatment of HD has yet to be developed. Therapeutic discovery research in HD has been reported using yeast, cells derived from transgenic animal models and HD patients, and induced pluripotent stem cells from patients. A transgenic nonhuman primate model of HD (HD monkey) shows neuropathological, behavioral, and molecular changes similar to an HD patient. In addition, neural progenitor cells (NPCs) derived from HD monkeys can be maintained in culture and differentiated to neural cells with distinct HD cellular phenotypes including the formation of mHTT aggregates, intranuclear inclusions, and increased susceptibility to oxidative stress. Here, we evaluated the potential application of HD monkey NPCs and neural cells as an in vitro model for HD drug discovery research.

Entities:  

Keywords:  Huntington’s disease; drug screening; monkey model; neural cells; pluripotent stem cells

Mesh:

Substances:

Year:  2016        PMID: 28027448      PMCID: PMC5699456          DOI: 10.1177/2472555216685044

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  29 in total

1.  Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.

Authors:  Austen J Milnerwood; Alexandra M Kaufman; Marja D Sepers; Clare M Gladding; Lily Zhang; Liang Wang; Jing Fan; Ainsley Coquinco; Joy Yi Qiao; Hwan Lee; Yu Tian Wang; Max Cynader; Lynn A Raymond
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 2.  Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.

Authors:  Tiago Fleming Outeiro; Flaviano Giorgini
Journal:  Biotechnol J       Date:  2006-03       Impact factor: 4.677

3.  Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

4.  Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.

Authors:  Soon-Tae Lee; Kon Chu; Jung-Eun Park; Lami Kang; Song-Yi Ko; Keun-Hwa Jung; Manho Kim
Journal:  Brain Res       Date:  2006-09-07       Impact factor: 3.252

5.  Riluzole is a potent drug to protect neonatal rat hypoglossal motoneurons in vitro from excitotoxicity due to glutamate uptake block.

Authors:  Alessandra Cifra; Francesca Nani; Andrea Nistri
Journal:  Eur J Neurosci       Date:  2011-02-17       Impact factor: 3.386

6.  Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells.

Authors:  Ningzhe Zhang; Mahru C An; Daniel Montoro; Lisa M Ellerby
Journal:  PLoS Curr       Date:  2010-10-28

7.  A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.

Authors:  Robert C Murphy; Anne Messer
Journal:  Brain Res Mol Brain Res       Date:  2004-02-05

8.  Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.

Authors:  Keith A Wesnes; Dag Aarsland; Clive Ballard; Elisabet Londos
Journal:  Int J Geriatr Psychiatry       Date:  2014-04-16       Impact factor: 3.485

9.  Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease.

Authors:  Dayu Sun; Junhua Chen; Xiaohang Bao; Yulong Cai; Jinghui Zhao; Jing Huang; Wei Huang; Xiaotang Fan; Haiwei Xu
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

10.  Genomic Analysis Reveals Disruption of Striatal Neuronal Development and Therapeutic Targets in Human Huntington's Disease Neural Stem Cells.

Authors:  Karen L Ring; Mahru C An; Ningzhe Zhang; Robert N O'Brien; Eliana Marisa Ramos; Fuying Gao; Robert Atwood; Barbara J Bailus; Simon Melov; Sean D Mooney; Giovanni Coppola; Lisa M Ellerby
Journal:  Stem Cell Reports       Date:  2015-12-08       Impact factor: 7.765

View more
  3 in total

1.  FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.

Authors:  Yanying Liu; Fangfang Qiao; Patricia C Leiferman; Alan Ross; Evelyn H Schlenker; Hongmin Wang
Journal:  Hum Mol Genet       Date:  2017-11-15       Impact factor: 6.150

2.  Chromatin accessibility and transcription dynamics during in vitro astrocyte differentiation of Huntington's Disease Monkey pluripotent stem cells.

Authors:  Alexandra V Goodnight; Isaac Kremsky; Sujittra Khampang; Yoon Hee Jung; James M Billingsley; Steven E Bosinger; Victor G Corces; Anthony W S Chan
Journal:  Epigenetics Chromatin       Date:  2019-11-13       Impact factor: 4.954

Review 3.  Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.

Authors:  Maria Csobonyeiova; Stefan Polak; Lubos Danisovic
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.